Clinical trialPhase 1Completed
A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Tumors
A Phase 1 First-in-human Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Malignant Tumors
- Outcome
- Finished, no results posted
- Phase
- Phase 1
- Status
- Completed
- Study type
- Interventional
- Start
- 31 March 2022
- Expected end
- 16 August 2024
- Enrollment
- 77 participants
- Sites
- 29
- Primary outcomes
- Number of participants with adverse events (AEs); Number of participants with serious adverse events (SAEs); Number of participants with AEs meeting protocol defined dose-limiting toxicity (DLT) criteria; Number of participants with AEs leading to discontinuation; Number of participants with death
- Sponsor
- Industry
- Results posted
- No
- Last update
- 26 September 2024
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The purpose of this study is to assess the safety and tolerability of BMS-986406 administered alone, in combination with nivolumab, or in combination with nivolumab and platinum-doublet chemotherapy (PDCT) in participants with advanced tumors.